Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Polyphor AG    POLN   CH0106213793

POLYPHOR AG (POLN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 11:31:12 am
20.9 CHF   +3.47%
 SummaryQuotesChartsNewsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
18(c) 18.82(c) 20.5(c) 20.2(c) 20.9(c) Last
5 414 5 015 23 406 5 353 5 342 Volume
-1.85% +4.56% +8.93% -1.46% +3.47% Change
More quotes
Financials (CHF)
Sales 2018 9,54 M
EBIT 2018 -47,6 M
Net income 2018 -47,9 M
Finance 2018 131 M
Yield 2018 -
Sales 2019 15,3 M
EBIT 2019 -39,4 M
Net income 2019 -56,0 M
Finance 2019 90,9 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 10,5x
EV / Sales2019 9,14x
Capitalization 231 M
More Financials
Company
Polyphor AG is a Switzerland-based company, which is engaged in the development of novel antibiotics and other efficacious therapies. The Company's medicines pipeline includes Murepavadin (POL7080), a novel class of specific outer membrane protein targeting antibiotic to treat resistant Pseudomonas... 
Sector
Pharmaceuticals
Calendar
03/04Earnings Release
More about the company
Latest news on POLYPHOR AG
2018POLYPHOR : announces positive results from the FDA Type B Guidance meeting on th..
EQ
2018POLYPHOR : wins the Swiss Technology Award 2018
EQ
2018POLYPHOR : Balixafortide combination with eribulin in metastatic breast cancer d..
EQ
2018POLYPHOR : announces protocol agreement with the FDA for the second pivotal Phas..
EQ
2018POLYPHOR : CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the tra..
EQ
2018POLYPHOR : to present new survival data for balixafortide at the 2018 European S..
EQ
2018POLYPHOR : announces financial results for the first half 2018
EQ
2018POLYPHOR : Novo Holdings invests CHF 6.8 Million in Polyphor to accelerate the d..
EQ
2018POLYPHOR : announces listing of new shares related to the convertible loan facil..
EQ
More news
Sector news : Biopharmaceuticals
01/18ELI LILLY AND : Lilly Reports Favorable Cyramza Results in Phase 3 Liver Cancer ..
DJ
01/18ABBVIE : Says Imbruvica Didn't Meet Endpoints in Pancreatic Cancer Study
DJ
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/18FDA Approves Herceptin Biosimilar Ontruzant Breast Cancer Drug
DJ
01/18ELI LILLY AND : Sarcoma Drug Combo Proves Ineffective in Trials--Update
DJ
More sector news : Biopharmaceuticals
Chart POLYPHOR AG
Duration : Period :
Polyphor AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POLYPHOR AG
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 60,0  CHF
Spread / Average Target 187%
Managers
NameTitle
Giacomo di Nepi Chief Executive Officer
Argeris N. Karabelas Chairman
Kalina Scott Chief Financial Officer
Daniel Obrecht Chief Scientific Officer
Frank Weber Director, Chief Medical & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
POLYPHOR AG17.15%232
BIOGEN12.13%67 984
CSL LIMITED5.96%63 903
ALEXION PHARMACEUTICALS20.22%26 113
BIOMARIN PHARMACEUTICAL14.52%17 395
GRIFOLS6.72%16 880